350+
Mandarin, Cantonese, English and Japanese
Commerce & Finance Law Offices (“C&F”) is one of the best commercial law firms in China. Faithfully adhering to the principles of professional integrity and excellence, C&F focuses on solving the clients’ most demanding and important problems, and provides one-stop solutions and strive to provide clients with pragmatic and cost-effective legal solutions that meet their best interests. C&F has steadily built up its well-recognized practice and reputation in the fields of following:
- Capital Markets
- Corporate M&A
- Private Equity
- New Economy (TMT/Education/Healthcare)
- Banking & Finance
- Dispute Resolution
- Insolvency & Restructuring
- Investment Funds
- Intellectual Property
- Foreign Investment
All key practice contacts:
Bd.list@tongshang.com
Recent transactional highlights:
- C&F advises Joint-sponsor and underwriter on the listing of China Tower Corporation Limited (stock code: 0788.HK) on the Main Board of the Stock Exchange of Hong Kong. The deal is The world’s largest initial public offering (“IPO”) in 2018, the Hong Kong’s largest IPO in nearly eight years, the No. 4 biggest IPO in the thirty years of HKSE, and the world’s largest IPO in the telecom industry
- C&F advises Joint-sponsor and underwriter on the IPO and listing of Innovent Biologics, Inc (stock code: 01801.HK) on the Main Board of the Stock Exchange of Hong Kong. The deal is the biggest global IPO of Pre-revenue biotech company.
- C&F advises the sponsor on the listing of Ascletis Pharma Inc.(stock code: 1672.HK) on the Main Board of the Stock Exchange of Hong Kong. Ascletis Pharma Inc is the first successful IPO biopharmaceutical company after the implementation of the new rules of the Hong Kong Stock Exchange
- C&F advises China Renaissance on its listing on the Main Board of the Stock Exchange of Hong Kong. China Renaissance is the first listed private equity institution that adopted VIE structure.
- C&F advises Maoyan Entertainment(stock code: 1896.HK) on its reorganization and listing on the Stock Exchange of Hong Kong. The listing of Maoyan Entertainment is a milestone event in the area of entertainment in China and the deal size of the IPO is one of the largest projects in the recent years in the area of entertainment in China.
- C&F advises COSCO Shipping Holdings on acquiring Orient Overseas (International) jointly with Shanghai International Port. The transaction with a total amount of HK$49.2 billion has been one of the most influential M&A transactions in the Asia-Pacific capital market since 2017.
- C&F advises Bilibili(stock code: BILI) on its listing on the Nasdaq. The total amount raised in this offering is US$483 million.
- C&F advises the managers on the issuing of $64bn-equivalent dual-currency, multi-tranche bond issued by China National Chemical Corporation. The Large-than-expected bonds were divided into six tranches in total, five in US dollars, and one in €1.2bn euro, which were traded well on SGX and ISE respectively.
- C&F advises the underwriters on the issuing of USD1.75 billion & EUR850 million MTNs issued by State Grid Corporation of China. The deal was a Medium Term Note of USD10 billion after upsizing from USD7.7 billion, under which USD1.75 billion & EUR850 million were issued and 16 underwriters were involved.
- C&F advises Kohlberg Kravis Roberts & Co. L.P on the acquisition of Anhui Hetian Hospital's Controlling Stockholder. C&F creatively draft a series of compliance mechanisms after one month discussion with US compliance counsel to ensure the operation of the targeted company conform to US regulation.
- C&F advises the strategic investor on the bankruptcy and reorganization of Bohai Steel Group. The reorganization covers 48 enterprises of the Bohai Steel Group, with a total debt of more than 200 billion yuan, which is the largest reorganization cases in China in terms of the amount of related assets and liabilities.
- C&F advises in an arbitration administrated by LCIA between a Singapore registered company and a Hong Kong registered company. The amount of this dispute is more than USD 900,000,000 and it is so complicated that connected with international trade, tariffs, anti-dumping and countervailing investigations, veil piercing of companies, etc.
Beijing Office
6F and 5F NCI Tower, A12 Jianguomenwai Avenue Chaoyang ,
Beijing, 100022
China
T: +86 10-65693399
F: +86 10-65693838
E: Beijing@tongshang.com W: www.tongshang.com
Shanghai Office
10F, Block 1, Jingan Kerry Center, Nanjing West Road,
Shanghai, 200040
China
T: +86 21-60192600
F: +86 21-60192697
E: Shanghaifs@tongshang.com W: www.tongshang.com
Shenzhen Office
2301, Block A, Aerospace Science and Technology Plaza, Haide 3rd Road, Nanshan District,
Shenzhen, 518067
China
T: +86 755-83517570
F: +86 755-83515502
E: Shenzhenfs@tongshang.com W: www.tongshang.com
Hongkong Office
29/F, 238 Des Voeux Road Central,
Hong Kong
China
T: +852 2151 5150
F: +852 2151 5158
E: hongkong@tongshang.com W: www.tongshang.com
